Related Experiment Video
Updated: Oct 11, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Use of Cardiac Contractility Modulation in an Older Patient with Non-Ischemic Dilated Cardiomyopathy: A Case Report
Gianvito Manganelli1, Antonio Fiorentino2, Gianluca Ceravolo2
1Cardiology Department, ASL Avellino-Sant'Ottone Frangipane Hospital, 83031 Ariano Irpino, Italy.
Abstract:
Cardiac contractility modulation (CCM) is a novel device-based therapy used in patients with HFrEF. CCM therapy is associated with an improvement in exercise tolerance, increased quality of life, reduced HF hospitalizations, and reverse remodelling of the left ventricle in patients with HFrEF. In this case, we report the clinical benefit of CCM in an older patient with advanced HFrEF due to ischemic dilated cardiomyopathy with frequent heart failure-related hospitalizations and poor quality of life despite optimal medical therapy.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VI: Nursing Management
Heart Failure V: Medical Management

